Trial · NCT03919175
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
NCT03919175, Phase 2, Terminated, Massachusetts General Hospital; results first posted 2026-02-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma. Trials, record NCT03919175. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03919175
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
- NCT number
- NCT03919175
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 18 participants, actual
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Lymphoma, Follicular Lymphoma, Follicular Lymphoma, Grade 1, Follicular Lymphoma Grade 2, Follicular Lymphoma Grade IIIa, Marginal Zone Lymphoma, Marginal Zone B Cell Lymphoma
- Interventions
- Umbralisib, Rituximab
- First posted
- 2019-04-18
- Last updated
- 2026-02-27
- Results first posted
- 2026-02-27
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Response Rate | 2 years | The frequency of patients who achieve a complete response per 2014 Lugano criteria. |
| Secondary | Overall Response Rate | 2 years | The frequency of patients who achieve a complete or partial response per 2014 Lugano criteria |
| Secondary | Progression Free Survival | 2 years | The median progression-free survival using Kaplan-Meier method with time of registration as time origin. |
| Secondary | Overall Survival | 2 Years | The median overall survival using Kaplan-Meier method with time of registration as time origin. |
| Secondary | Number of Participants With Adverse Events | 2 years |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Complete Response Rate | 2 years | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Overall Response Rate | 2 years | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Progression Free Survival | 2 years | years | MEDIAN | |
| SECONDARY | Overall Survival | 2 Years | years | MEDIAN | |
| SECONDARY | Number of Participants With Adverse Events | 2 years | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Complete Response Rate | Umbralisib+Rituximab | 7 | Participants | ||
| Overall Response Rate | Umbralisib+Rituximab | Complete response | 7 | Participants | |
| Overall Response Rate | Umbralisib+Rituximab | Partial response | 7 | Participants | |
| Overall Response Rate | Umbralisib+Rituximab | Stable disease | 4 | Participants | |
| Overall Response Rate | Umbralisib+Rituximab | Progressive disease | 0 | Participants | |
| Progression Free Survival | Umbralisib+Rituximab | NA | 90% Confidence Interval NA to NA | years | |
| Overall Survival | Umbralisib+Rituximab | NA | 90% Confidence Interval NA to NA | years | |
| Number of Participants With Adverse Events | Umbralisib+Rituximab | 15 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Umbralisib+Rituximab | 18 | |
| Overall Study | COMPLETED | Umbralisib+Rituximab | 18 | |
| Overall Study | NOT COMPLETED | Umbralisib+Rituximab | 0 |
Source ClinicalTrials.gov
Adverse events114
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | General disorders | Umbralisib+Rituximab | 15 | 18 | |
| other | Diarrhea | Gastrointestinal disorders | Umbralisib+Rituximab | 14 | 18 | |
| other | Nausea | Gastrointestinal disorders | Umbralisib+Rituximab | 11 | 18 | |
| other | Aspartate aminotransferase increased | Investigations | Umbralisib+Rituximab | 8 | 18 | |
| other | Abdominal pain | Gastrointestinal disorders | Umbralisib+Rituximab | 7 | 18 | |
| other | Alanine aminotransferase increased | Investigations | Umbralisib+Rituximab | 7 | 18 | |
| other | Anxiety | Psychiatric disorders | Umbralisib+Rituximab | 7 | 18 | |
| other | Insomnia | Psychiatric disorders | Umbralisib+Rituximab | 7 | 18 | |
| other | Rash maculo-papular | Skin and subcutaneous tissue disorders | Umbralisib+Rituximab | 6 | 18 | |
| other | Anorexia | Metabolism and nutrition disorders | Umbralisib+Rituximab | 5 | 18 |
1 to 10 of 114Source ClinicalTrials.gov
See all 114 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Umbralisib+Rituximab | 2 | 18 |
| Total, other adverse events | Umbralisib+Rituximab | 15 | 18 |
| Total, serious adverse events | Umbralisib+Rituximab | 9 | 18 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03919175
GET https://conductscience.org/api/trials/v1/NCT03919175/events?page=2